These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 24577998)
1. An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control. Lin SY Pharm Res; 2014 Jul; 31(7):1619-31. PubMed ID: 24577998 [TBL] [Abstract][Full Text] [Related]
2. Thermodynamic and kinetic characterization of polymorphic transformation of famotidine during grinding. Lin SY; Cheng WT; Wang SL Int J Pharm; 2006 Aug; 318(1-2):86-91. PubMed ID: 16647827 [TBL] [Abstract][Full Text] [Related]
3. Optimization and validation of a dissolution test for famotidine tablets using flow injection analysis. Tzanavaras PD; Verdoukas A; Balloma T J Pharm Biomed Anal; 2006 May; 41(2):437-41. PubMed ID: 16413732 [TBL] [Abstract][Full Text] [Related]
5. Studies on the influence of β-cyclodextrin derivatives on the physical stability of famotidine. Jamrógiewicz M; Milewska K Spectrochim Acta A Mol Biomol Spectrosc; 2019 Aug; 219():346-357. PubMed ID: 31055241 [TBL] [Abstract][Full Text] [Related]
6. Famotidine polymorphic transformation in the grinding process significantly depends on environmental humidity or water content. Cheng WT; Lin SY Int J Pharm; 2008 Jun; 357(1-2):164-8. PubMed ID: 18403143 [TBL] [Abstract][Full Text] [Related]
7. Selection of generic preparations of famotidine orally disintegrating tablets for use in unit-dose packages. Yamazaki N; Iizuka R; Miyazawa S; Wada Y; Shimokawa K; Ishii F Drug Discov Ther; 2012 Oct; 6(5):263-8. PubMed ID: 23229147 [TBL] [Abstract][Full Text] [Related]
8. Characterization and selective crystallization of famotidine polymorphs. Lu J; Wang XJ; Yang X; Ching CB J Pharm Sci; 2007 Sep; 96(9):2457-68. PubMed ID: 17518361 [TBL] [Abstract][Full Text] [Related]
9. Polymorphism and crystallization of active pharmaceutical ingredients (APIs). Lu J; Rohani S Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600 [TBL] [Abstract][Full Text] [Related]
10. In vitro interactions of captopril with H2-receptor antagonists. Sultana N; Arayne MS; Quraish R Pak J Pharm Sci; 2007 Apr; 20(2):132-9. PubMed ID: 17416569 [TBL] [Abstract][Full Text] [Related]
11. Differential scanning calorimetry with curve-fitting program used to quantitatively analyze the polymorphic transformation of famotidine in the compressed compact. Cheng WT; Lin SY; Wang SL Drug Dev Ind Pharm; 2008 Dec; 34(12):1368-75. PubMed ID: 18720143 [TBL] [Abstract][Full Text] [Related]
12. Solid-state supramolecular synthesis based on the N-H…O heterosynthon: an approach to solve the polymorphism problem in famotidine. Russo MG; Brusau EV; Ellena J; Narda GE J Pharm Sci; 2014 Nov; 103(11):3754-3763. PubMed ID: 25277273 [TBL] [Abstract][Full Text] [Related]
13. Development of modified dosage form for enhancement of dissolution rate through amalgamation of solid dispersion and cube sugar or sintering technology using famotidine as a model drug. Gupta V; Gupta M; Madan AK PDA J Pharm Sci Technol; 2009; 63(1):58-70. PubMed ID: 19455942 [TBL] [Abstract][Full Text] [Related]
14. [Analytical application of phosphotungstic acid complexes. Fabrication and characterisation of membrane selective electrodes for some H2 antihistaminics]. Apostu M; Dorneanu V Rev Med Chir Soc Med Nat Iasi; 2008; 112(3):856-9. PubMed ID: 20201281 [TBL] [Abstract][Full Text] [Related]
15. Application of vibrational spectroscopy, thermal analyses and X-ray diffraction in the rapid evaluation of the stability in solid-state of ranitidine, famotidine and cimetidine. Jamrógiewicz M; Ciesielski A J Pharm Biomed Anal; 2015 Mar; 107():236-43. PubMed ID: 25625474 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study. Abourehab MA; Khaled KA; Sarhan HA; Ahmed OA Drug Des Devel Ther; 2015; 9():2159-69. PubMed ID: 25926722 [TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of famotidine polymorphs. Nagaraju R; Prathusha AP; Subhash Chandra Bose P; Kaza R; Bharathi K Curr Drug Discov Technol; 2010 Jun; 7(2):106-16. PubMed ID: 20836758 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Fahmy RH; Kassem MA Eur J Pharm Biopharm; 2008 Aug; 69(3):993-1003. PubMed ID: 18396390 [TBL] [Abstract][Full Text] [Related]
19. Crystalline and amorphous famotidine malate as pathways to prevent polymorphic transformation with improved dissolution. Russo MG; Brusau EV; Ellena J; Narda GE Int J Pharm; 2023 Jul; 642():123053. PubMed ID: 37196883 [TBL] [Abstract][Full Text] [Related]
20. Physico-chemical comparison of famotidine tablets prepared via dry granulation and direct compression techniques. Baseer A; Hassan F; Hassan SF; Jabeen S; Israr F; Murtaza G; Haque N Pak J Pharm Sci; 2013 May; 26(3):439-43. PubMed ID: 23625414 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]